Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Denosumab: a novel antiresorptive drug for osteoporosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Women's lived experiences of learning to live with osteoporosis: a longitudinal qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.

Original languageEnglish
JournalCleveland Clinic Journal of Medicine
Volume82
Issue number2
Pages (from-to)105-14
Number of pages10
ISSN0891-1150
DOIs
Publication statusPublished - Feb 2015

    Research areas

  • Absorptiometry, Photon, Aged, Antibodies, Monoclonal, Humanized, Bone Density, Bone Density Conservation Agents, Denosumab, Female, Humans, Lumbar Vertebrae, Osteoporosis, Osteoporotic Fractures, RANK Ligand, Spinal Fractures, Thoracic Vertebrae

ID: 45982805